|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 2 (July 15), 1999:
pp. 803-807
Prevalence of the Inactivating 609C T Polymorphism
in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With
Primary and Therapy-Related Myeloid Leukemia
Richard A. Larson,
Yunxia Wang,
Mekhala Banerjee,
Joseph Wiemels,
Christine Hartford,
Michelle M. Le Beau, and
Martyn T. Smith
From the Section of Hematology/Oncology, Department of Medicine and
the Cancer Research Center of the University of Chicago, Chicago, IL;
and the Division of Environmental Health Sciences, School of Public
Health, University of California, Berkeley, CA.
NAD(P)H:quinone oxidoreductase (NQO1) converts benzene-derived
quinones to less toxic hydroquinones and has been implicated in
benzene-associated hematotoxicity. A point mutation in codon 187 (Pro
to Ser) results in complete loss of enzyme activity in homozygous
subjects, whereas those with 2 wild-type alleles have normal activity.
The frequency of homozygosity for the mutant allele among Caucasians
and African Americans is 4% to 5% but is higher in Hispanics and
Asians. Using an unambiguous polymerase chain reaction (PCR) method, we
assayed nonmalignant lymphoblastoid cell lines derived from 104 patients with myeloid leukemias; 56 had therapy-related acute myeloid
leukemia (t-AML), 30 had a primary myelodysplastic syndrome (MDS), 9 had AML de novo, and 9 had chronic myelogenous leukemia (CML). All
patients had their leukemia cells karyotyped. Eleven percent of the
t-AML patients were homozygous and 41% were heterozygous for the NQO1
polymorphism; these proportions were significantly higher than those
expected in a population of the same ethnic mix (P = .036).
Of the 45 leukemia patients who had clonal abnormalities of chromosomes
5 and/or 7, 7 (16%) were homozygous for the inactivating polymorphism,
17 (38%) were heterozygous, and 21 (47%) had 2 wild-type alleles for
NQO1. Thus, NQO1 mutations were significantly increased compared with
the expected proportions: 5%, 34%, and 61%, respectively (P
= .002). An abnormal chromosome no. 5 or 7 was observed in 7 of 8 (88%) homozygotes, 17 of 45 (38%) heterozygotes, and 21 of 51 (41%) patients with 2 wild-type alleles. Among 33 patients with balanced translocations [14 involving bands 11q23 or 21q22, 10 with inv(16) or
t(15;17), and 9 with t(9;22)], there were no homozygotes, 15 (45%)
heterozygotes, and 18 (55%) with 2 wild-type alleles. Whereas fewer
than 3 homozygotes were expected among the 56 t-AML patients, 6 were
observed; 19 heterozygotes were expected, but 23 were observed. The
gene frequency for the inactivating polymorphism (0.31) was increased
approximately 1.4-fold among the 56 t-AML patients. This increase was
observed within each of the following overlapping cohorts of t-AML
patients: the 43 who had received an alkylating agent, the 27 who had
received a topoisomerase II inhibitor, and the 37 who had received any
radiotherapy. Thus, the frequency of an inactivating polymorphism in
NQO1 appears to be increased in this cohort of myeloid leukemias,
especially among those with t-AML or an abnormality of chromosomes 5 and/or 7. Homozygotes and heterozygotes (who are at risk for
treatment-induced mutation or loss of the remaining wild-type allele in
their hematopoietic stem cells) may be particularly vulnerable to
leukemogenic changes induced by carcinogens.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Stanulla, C. Dynybil, D. B. Bartels, M. Dordelmann, L. Loning, A. Claviez, and M. Schrappe
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group
Haematologica,
November 1, 2007;
92(11):
1581 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Voso, E Fabiani, F D'Alo', F Guidi, A Di Ruscio, S Sica, L Pagano, M Greco, S Hohaus, and G Leone
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes
Ann. Onc.,
September 1, 2007;
18(9):
1523 - 1528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Jawad, G Giotopoulos, C Cole, and M Plumb
Target cell frequency is a genetically determined risk factor in radiation leukaemogenesis
Br. J. Radiol.,
September 1, 2007;
80(Special_Issue_1):
S56 - S62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Smith, L. J. Worrillow, and J. M. Allan
A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia
Blood,
February 1, 2007;
109(3):
1233 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Larson
Etiology and Management of Therapy-Related Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kannan and A. K. Jaiswal
Low and High Dose UVB Regulation of Transcription Factor NF-E2-Related Factor 2.
Cancer Res.,
September 1, 2006;
66(17):
8421 - 8429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal
Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis
J. Biol. Chem.,
July 21, 2006;
281(29):
19798 - 19808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Umemura, Y. Kuroiwa, Y. Kitamura, Y. Ishii, K. Kanki, Y. Kodama, K. Itoh, M. Yamamoto, A. Nishikawa, and M. Hirose
A Crucial Role of Nrf2 in In Vivo Defense against Oxidative Damage by an Environmental Pollutant, Pentachlorophenol
Toxicol. Sci.,
March 1, 2006;
90(1):
111 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Li, Z. Liu, E. M. Sturgis, R. M. Chamberlain, M. R. Spitz, and Q. Wei
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu Polymorphisms Are Not Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2005;
14(4):
1034 - 1036.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Iskander, A. Gaikwad, M. Paquet, D. J. Long II, C. Brayton, R. Barrios, and A. K. Jaiswal
Lower Induction of p53 and Decreased Apoptosis in NQO1-Null Mice Lead to Increased Sensitivity to Chemical-Induced Skin Carcinogenesis
Cancer Res.,
March 15, 2005;
65(6):
2054 - 2058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Avogbe, L. Ayi-Fanou, H. Autrup, S. Loft, B. Fayomi, A. Sanni, P. Vinzents, and P. Moller
Ultrafine particulate matter and high-level benzene urban air pollution in relation to oxidative DNA damage
Carcinogenesis,
March 1, 2005;
26(3):
613 - 620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Siegel, D. L. Gustafson, D. L. Dehn, J. Y. Han, P. Boonchoong, L. J. Berliner, and D. Ross
NAD(P)H:Quinone Oxidoreductase 1: Role as a Superoxide Scavenger
Mol. Pharmacol.,
May 1, 2004;
65(5):
1238 - 1247.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Seedhouse, R. Faulkner, N. Ashraf, E. Das-Gupta, and N. Russell
Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia
Clin. Cancer Res.,
April 15, 2004;
10(8):
2675 - 2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stiborova, E. Frei, B. Sopko, K. Sopkova, V. Markova, M. Lankova, T. Kumstyrova, M. Wiessler, and H. H. Schmeiser
Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase
Carcinogenesis,
October 1, 2003;
24(10):
1695 - 1703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Libura, V. Asnafi, A. Tu, E. Delabesse, I. Tigaud, F. Cymbalista, A. Bennaceur-Griscelli, P. Villarese, G. Solbu, A. Hagemeijer, et al.
FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress
Blood,
September 15, 2003;
102(6):
2198 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Smith, M. M. Le Beau, D. Huo, T. Karrison, R. M. Sobecks, J. Anastasi, J. W. Vardiman, J. D. Rowley, and R. A. Larson
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Blood,
July 1, 2003;
102(1):
43 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Bodell, N. W. Gaikwad, D. Miller, and M. S. Berger
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide: Implications for the Treatment of Low-Grade Adult and Pediatric Brain Tumors
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2003;
12(6):
545 - 551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
Blood,
May 15, 2003;
101(10):
3862 - 3867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang, W. A. Schulz, Y. Li, R. Wang, R. Zotz, D. Wen, D. Siegel, D. Ross, H. E. Gabbert, and M. Sarbia
Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population
Carcinogenesis,
May 1, 2003;
24(5):
905 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Bowen, M. E. Frew, S. Rollinson, P. L. Roddam, A. Dring, M. T. Smith, S. E. Langabeer, and G. J. Morgan
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication
Blood,
April 1, 2003;
101(7):
2770 - 2774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Boulton, C. Cole, A. Knight, H. Cleary, R. Snowden, and M. Plumb
Low-penetrance genetic susceptibility and resistance loci implicated in the relative risk for radiation-induced acute myeloid leukemia in mice
Blood,
March 15, 2003;
101(6):
2349 - 2354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Anwar, D. Dehn, D. Siegel, J. K. Kepa, L. J. Tang, J. A. Pietenpol, and D. Ross
Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems
J. Biol. Chem.,
March 14, 2003;
278(12):
10368 - 10373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zappa, T. Ward, E. Pedrinis, J. Butler, and A. McGown
NAD(P)H:Quinone Oxidoreductase 1 Expression in Kidney Podocytes
J. Histochem. Cytochem.,
March 1, 2003;
51(3):
297 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Smith, Y. Wang, C. F. Skibola, D. J. Slater, L. L. Nigro, P. C. Nowell, B. J. Lange, and C. A. Felix
Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children
Blood,
December 15, 2002;
100(13):
4590 - 4593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Long II, K. Iskander, A. Gaikwad, M. Arin, D. R. Roop, R. Knox, R. Barrios, and A. K. Jaiswal
Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity
J. Biol. Chem.,
November 22, 2002;
277(48):
46131 - 46139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Seedhouse, R. Bainton, M. Lewis, A. Harding, N. Russell, and E. Das-Gupta
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia
Blood,
November 15, 2002;
100(10):
3761 - 3766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Long II, A. Gaikwad, A. Multani, S. Pathak, C. A. Montgomery, F. J. Gonzalez, and A. K. Jaiswal
Disruption of the NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Gene in Mice Causes Myelogenous Hyperplasia
Cancer Res.,
June 1, 2002;
62(11):
3030 - 3036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hamajima, T. Saito, K. Matsuo, and K. Tajima
Competitive Amplification and Unspecific Amplification in Polymerase Chain Reaction with Confronting Two-Pair Primers
J. Mol. Diagn.,
May 1, 2002;
4(2):
103 - 107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al.
p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer
Clin. Cancer Res.,
May 1, 2002;
8(5):
973 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Winski, Y. Koutalos, D. L. Bentley, and D. Ross
Subcellular Localization of NAD(P)H:quinone Oxidoreductase 1 in Human Cancer Cells
Cancer Res.,
March 1, 2002;
62(5):
1420 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Krajinovic, D. Labuda, G. Mathonnet, M. Labuda, A. Moghrabi, J. Champagne, and D. Sinnett
Polymorphisms in Genes Encoding Drugs and Xenobiotic Metabolizing Enzymes, DNA Repair Enzymes, and Response to Treatment of Childhood Acute Lymphoblastic Leukemia
Clin. Cancer Res.,
March 1, 2002;
8(3):
802 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Strassburg, C. P. Strassburg, M. P. Manns, and R. H. Tukey
Differential Gene Expression of NAD(P)H:Quinone Oxidoreductase and NRH:Quinone Oxidoreductase in Human Hepatocellular and Biliary Tissue
Mol. Pharmacol.,
February 1, 2002;
61(2):
320 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology,
January 1, 2002;
2002(1):
162 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
PNAS,
September 5, 2001;
(2001)
191211198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Blanco, T. Dervieux, M. J. Edick, P. K. Mehta, J. E. Rubnitz, S. Shurtleff, S. C. Raimondi, F. G. Behm, C.-H. Pui, and M. V. Relling
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia
PNAS,
August 28, 2001;
98(18):
10338 - 10343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Alexander, S. L. Patheal, A. Biondi, S. Brandalise, M.-E. Cabrera, L. C. Chan, Z. Chen, G. Cimino, J.-C. Cordoba, L.-J. Gu, et al.
Transplacental Chemical Exposure and Risk of Infant Leukemia with MLL Gene Fusion
Cancer Res.,
March 1, 2001;
61(6):
2542 - 2546.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Siegel, A. Anwar, S. L. Winski, J. K. Kepa, K. L. Zolman, and D. Ross
Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1
Mol. Pharmacol.,
February 1, 2001;
59(2):
263 - 268.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. J. Long II, R. L. Waikel, X.-J. Wang, L. Perlaky, D. R. Roop, and A. K. Jaiswal
NAD(P)H:Quinone Oxidoreductase 1 Deficiency Increases Susceptibility to Benzo(a)pyrene-induced Mouse Skin Carcinogenesis
Cancer Res.,
November 1, 2000;
60(21):
5913 - 5915.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M.J. Lafuente, X. Casterad, M. Trias, C. Ascaso, R. Molina, A. Ballesta, S. Zheng, J.K. Wiencke, and A. Lafuente
NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors | |
